Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire

If youre looking for stocks that have the potential to make you a millionaire on a relatively modest investment, youre…

Targeted cancer drugs may replace chemo for some patients — and drugmakers say theyre getting closer

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) concluded the recent trading session at $73.55, signifying a -1.17% move from its prior days close.…

AstraZeneca enters into collaboration with CSPC

13 June 2025 AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research AstraZeneca has entered a strategic research collaboration with…

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $73.83, representing a +1.12% change from its previous close.…

IonQ treibt die Anwendung der quantenbeschleunigten Arzneimittelentwicklung zusammen mit AstraZeneca, AWS und NVIDIA voran

COLLEGE PARK, Maryland--(BUSINESS WIRE)--IonQ (NYSE: IONQ), ein führendes Unternehmen in der Quantencomputer- und Netzwerkbranche, veröffentlichte heute Ergebnisse eines von IonQ,…

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Mercks shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.…

Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?

If everyone only invested in what they fully understood, I suspect quite a few stocks wouldnt exist today. We can…

AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet

…

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.…

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.…

Total Voting Rights

2 June 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds By Reuters

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds…

Danaher Partners With AstraZeneca to Support Precision Medicine

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making…

Why Tempus AI Stock Plummeted This Week

Extending the more-than-4% slide that they experienced last week, shares of Tempus AI (NASDAQ: TEM) have suffered an even more…

Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine

…

A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today

Shares of Tempus AI (NASDAQ: TEM) are falling on Wednesday. One of Cathie Woods largest holdings, the companys stock plummeted…

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.…

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.…

Why AstraZeneca May Be 2025s Most Underrated Pharma Stock

…

Swedish Business Consortium to build AI Factory with NVIDIA

· AstraZeneca, Ericsson, Saab, SEB and Wallenberg Investments to tap new sovereign AI infrastructure · NVIDIA to open AI…

AstraZeneca CEO gains shares under performance plan By Investing.com

AstraZeneca CEO gains shares under performance plan…

The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust

Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst Blog.…

AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?

AZNs key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.…

Top Research Reports for Visa, AstraZeneca & Shell

Todays Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell…

FTSE 100 LIVE: Index starts higher, AstraZeneca and GSK hit by Trump social post

FTSE starts higher Traders hopeful after US-China talks Drug makers tumble on Trump post AstraZeneca falls 5% GSK down 3%…

FTSE 100 LIVE: Index starts higher on US-China hopes, miners rally whilst AstraZeneca tumbles

FTSE starts higher Traders hopeful after US-China talks Miners rally Drug makers tumble on Trump post AstraZeneca falls 5% GSK…

FTSE 100 LIVE: Stocks rise on US-China hopes, miners rally whilst AstraZeneca tumbles

FTSE starts higher Traders hopeful after US-China talks Miners rally Drug makers tumble on Trump post AstraZeneca falls 5% GSK…

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after…

Roche Underweight

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Roche auf "Underweight" mit einem Kursziel von 220 Franken belassen. Dass…

JPMorgan belässt Roche auf Underweight - Ziel 220 Franken

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Roche auf "Underweight" mit einem Kursziel von 220 Franken belassen. Dass…

AstraZeneca unveils new facility as part of multibillion-dollar investment in US manufacturing

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing facility in Rockville, Maryland, as part of its ongoing $3.5 billion…

Think Its Too Late to Buy Tempus AI? Heres the Biggest Reason Why Theres Still Time.

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like theyre standing on a dock watching…

Total Voting Rights

1 May 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

ROUNDUP 2: Astrazeneca droht Millionenstrafe in China - Aktie holt Verluste auf

(neu: Schlusskurs) CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker Gewinnsprung zum Jahresstart durch…

ROUNDUP: Astrazeneca droht Millionenstrafe in China - Aktie verliert nach Zahlen

CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker Gewinnsprung zum Jahresstart durch eine drohende Millionenstrafe in China…

AstraZeneca PLC 2025 Q1 - Results - Earnings Call Presentation

…

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the…

FTSE 100 flat amid HSBC, BP and AstraZeneca earnings updates

The FTSE 100 crept into positive territory in early trade on Tuesday before turning marginally negative as investors digested a…

AstraZeneca shares fall as revenue miss tempers strong Q1 earnings By Investing.com

AstraZeneca shares fall as revenue miss tempers strong Q1 earnings…

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.…

Massive Investment in US Manufacturing Triggers Wave of Career Opportunities

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and…

Tempus AI: Deal mit Pharma-Riesen – Aktie geht steil

Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig…

Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The companys…

Why Tempus AI Stock Is Skyrocketing Today

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain…

Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop…

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.…

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers…

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trumps trade policies. The 47th U.S. president decided to impose steep tariffs…